This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

SPRINT trial (nifedipine after MI)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The SPRINT trial had to be prematurely terminated after recruiting 1358 patients because the use of nifedipine increased mortality following acute myocardial infarction.

Patients were randomised within 48 hr of a myocardial infarction to:

  • nifedipine 60 mg/day
  • placebo

Mortality at 6 months in the placebo group was 13.3% compared to 15.4% in the nifedipine group.

The conclusion is that routine use of calcium channel blockers following myocardial infarction should be avoided.

Reference:

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.